M J Edelman|S S Sternberg - JoVE Visualize

Showing results (51-60 of 80) with videos related to

Pageof 8

Sort By:

Cancer Investigation|January 1, 1991

Fatal thrombocytopenia and liver failure associated with carboplatin therapyR H Hruban, S S Sternberg, P Meyers, et al.

Seminars in Oncology|April 14, 1999

Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancerC J Langer, D R Gandara, P Calvert, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1997

Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group studyD R Gandara, M J Edelman, J J Crowley, et al.

Biochemistry|September 16, 1997

Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblastsL J Robinson, W K Roberts, T T Ling, et al.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998

Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administrationD R Gandara, F Roila, D Warr, et al.

Cancer|July 10, 2001

Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxelM J Edelman, D R Gandara, D H Lau, et al.

Cancer Research|November 1, 1980

Biochemical, pharmacological, and phase I clinical evaluation of pseudoisocytidineT M Woodcock, T C Chou, C T Tan, et al.

Cancer Research|December 1, 1980

Phase I evaluation of succinylated Acinetobacter glutaminase-asparaginase in adultsR P Warrell, T C Chou, C Gordon, et al.

Annals of Surgery|April 1, 1986

En bloc pelvic lymphadenectomy and sphincter preservation in the surgical management of rectal cancerW E Enker, S J Pilipshen, M L Heilweil, et al.

Urology|March 29, 2000

Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutationM J Edelman, F J Meyers, T R Miller, et al.

Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:

Pageof 8

Cancer Investigation|January 1, 1991

Fatal thrombocytopenia and liver failure associated with carboplatin therapyR H Hruban, S S Sternberg, P Meyers, et al.

Seminars in Oncology|April 14, 1999

Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancerC J Langer, D R Gandara, P Calvert, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1997

Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group studyD R Gandara, M J Edelman, J J Crowley, et al.

Biochemistry|September 16, 1997

Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblastsL J Robinson, W K Roberts, T T Ling, et al.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998

Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administrationD R Gandara, F Roila, D Warr, et al.

Cancer|July 10, 2001

Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxelM J Edelman, D R Gandara, D H Lau, et al.

Cancer Research|November 1, 1980

Biochemical, pharmacological, and phase I clinical evaluation of pseudoisocytidineT M Woodcock, T C Chou, C T Tan, et al.

Cancer Research|December 1, 1980

Phase I evaluation of succinylated Acinetobacter glutaminase-asparaginase in adultsR P Warrell, T C Chou, C Gordon, et al.

Annals of Surgery|April 1, 1986

En bloc pelvic lymphadenectomy and sphincter preservation in the surgical management of rectal cancerW E Enker, S J Pilipshen, M L Heilweil, et al.

Urology|March 29, 2000

Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutationM J Edelman, F J Meyers, T R Miller, et al.

Pageof 8